Focus on the Scientific Committee

Linda BauldLinda Bauld

Professor of Health Policy, Director of the Institute of Social Marketing and Dean of Research
University of Stirling, UK

 

What area of cancer research do you specialise in and how did you get in to it? 
I am a behavioural scientist interested in the prevention of cancer. I’ve worked primarily in the area of smoking cessation and tobacco control, and more recently researching interventions to reduce the harmful use of alcohol. After a PhD at Edinburgh I held a postdoctoral fellowship at the University of Kent from 1997, the year New Labour were elected and were introducing a range of new public health policies. I got involved in evaluating the introduction of the world’s first national treatment service for smokers (NHS stop smoking services) at that point and my interest in prevention started from that.

 

What inspired you to forge a career in cancer research?

Four in ten cases of cancer in the UK (and other countries) are preventable through addressing behavioural risk factors like smoking, diet, physical activity, alcohol and UV exposure, for example. Yet prevention research and policy does not receive the same attention or level of investment as some other areas of research. I’m committed to making the case for prevention, to anyone who will listen, whenever possible.

 

What have you been working on most recently?
A new area in cancer prevention is tobacco harm reduction (THR). I chaired the NICE guidance group on this topic for two years and since then have worked closely with Cancer Research UK to commission new studies to fill research gaps on THR, particularly around electronic cigarettes. Along with colleagues at CRUK and Public Health England, I’ve helped establish the UK Electronic Cigarette Research Forum which is generating new collaborations and studies on this issue and also informing international debate. My own research team at the University of Stirling is also conducting research on this issue. We have 2.8 million e-cigarette users in the UK. It’s still controversial, but important.

What do you perceive to be the biggest challenges in cancer research?

There are many and in my role as CRUK’s cancer prevention champion I am learning more about the latest advances in diagnosis and treatment alongside my own areas of expertise. However, for me, identifying and making the case for effective prevention policies that involve not just individual behaviour change but also modifying the societal drivers of risk factors is the biggest challenge.

 

What do you consider to be the most exciting development in cancer research at present?

There are some very exciting funding opportunities that will bring together new multidisciplinary groups of researchers to answer important questions. This includes CRUK’s Grand Challenge scheme, the Catalyst scheme, and more broadly, multi-funder initiatives that CRUK is involved in – for example the next stage of the National Prevention Research Initiative is about to be launched.

 

What has been your biggest achievement to date?

Contributing to efforts to reduce rates of smoking in pregnancy in the UK and overseas. Smoking in pregnancy is still the leading preventable cause of neonatal and maternal morbidity and mortality. I’ve led a number of studies identifying effective interventions and also helped develop NICE and World Health Organisation guidance. Since 2011 I’ve chaired the smoking pregnancy ‘Challenge Group’ in England which developed a strategy to help meet government targets and continues to meet and develop resources, guidance and research on smoking in pregnancy through its members who represent many organisations (from baby charities, to the Royal Colleges and research groups) working on this issue.

 

About the Scientific Committee

 

What has been the biggest challenge of being a member of the Committee?

NCRI covers the full spectrum of cancer research and there is a lot I don’t know about many topics, so just understanding what will be covered and who is best placed to contribute has been challenging.

 

What have you enjoyed most about being on the Committee?

Meeting new colleagues from a range of disciplines and organisations and learning about the latest research, policy and practice developments that will be discussed at the conference.

 

Looking forward to the 2016 NCRI Cancer Conference

 

What are you looking forward to most about this year’s Conference?

The sessions are always excellent but I think it is the conversations at the conference that are most valuable – catching up with colleagues, discussing new research ideas and making new connections.

 

What is new for the 2016 Conference?

We have a symposium on cancer prevention at the population level that’s not been run before. It will focus on translating research evidence into policies that help prevent cancer using tobacco, alcohol and obesity policy as examples. Our three speakers – Susan Jebb from Oxford, Ann McNeill from Kings College and Tim Stockwell from the University of Victoria in Canada are well known internationally for their research on prevention and public health. It will be a bit different from other sessions but I’d encourage colleagues to come along on Monday 7 November at 11am.

 

What do you predict to be the highlights of this year’s Conference?

The range of plenary speakers at this year’s meeting is exciting and I expect will generate a lot of interest. I’m particularly interested in some of the content on science communication as it’s important that we find ways to communicate research findings as they emerge. I think Kat Arney’s plenary on Sunday 6 November, which looks behind the media headlines to discuss how we should talk about cancer research will be well worth attending.

 

What would you say to convince people to attend this year’s Conference? 

If you are interested in the full spectrum of cancer research, the NCRI Cancer Conference is not to be missed. Importantly you don’t need to be a researcher or clinician to attend. Many of the sessions are accessible and understandable to a range of audiences including patients and other members of the public.

 

How will attending the Conference benefit students and those in the early stages of their career?

The poster sessions are a great way to present new findings for PhDs, postdocs and other early career researchers. It’s also worth highlighting for the women attending, the workshop on Women in Science which Caroline Dive is convening on Monday 7 November at 17:35. This will be a great opportunity for women early in their career (and others ) to learn from other women who have forged a career in science and cancer research.

 

If you could sum up the conference in three words, what would it be and why?

Innovation, Collaboration, Communication – an invaluable opportunity for the cancer research community to get together, share ideas and new findings, and communicate the value of what we do.

 

Just for fun

 

What has life taught you?

How little I actually know. I’m still learning and hope to keep doing so for many years to come.

 

What do you enjoy doing outside of work?

I travel a lot with work but travelling with my family is more enjoyable and we’ve been fortunate enough to visit a number of different countries. I also enjoy running, going to the gym and have a membership at a local independent cinema in Edinburgh where I live.

 

Where would your dream holiday be?

My parents emigrated to Canada when I was a child and I spent my teenage years on Vancouver Island. I never appreciated it as a teenager but I now return most summers with my own family and I think it is one of the most beautiful places in the world.

 

Name three things you would take with you to a desert island.

My son and daughter and my husband. No contest!